Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics is well positioned because ZEVASKYN has already demonstrated strong efficacy, durability, and safety in clinical studies and is now approved, while its ability to treat larger wounds gives it a complementary advantage versus Vyjuvek in RDEB. Commercial momentum is building as 1Q26 revenue reached $8.7M, six QTC sites are active, 95% of commercially insured U.S. lives now have coverage policies, and management expects 7-10 QTCs at steady-state with 10-12 patients per month across the U.S. within the next several years. Operationally, the Cleveland facility appears efficient and scalable, with a 25-day biopsy-to-graft turnaround, 45 technicians supporting up to 80-90% of maximum throughput, and expansion plans that could lift capacity materially, supporting a path to sustainably cash flow-positive status at under $100M in annualized revenue run rate.

Abeona Therapeutics is viewed negatively because its lead gene therapy faces unusually high manufacturing, certification, clinical, regulatory, and reimbursement risk, all of which are amplified by the complexity and cost of autologous cell-based products. Recent operating results reinforce that concern: 2Q revenue of $11.4M fell short of the $13.4M/$12.1M expectations, only four of five treated patients were billable, and a low manufacturing yield plus an out-of-spec product, biopsy quality issues, and a failed identity test all point to fragile execution. Even with seven active QTCs and a ~$1B rNPV for ZEVASKYN, the outlook remains pressured by possible slower-than-projected uptake, a 5% to 10% production failure rate, and potential financing or dilution risk.